Viagra is now being used to treat not only erectile dysfunction (ED) but also pulmonary hypertension. And the drug may have potential for treating several other conditions, according to a recent report. The three ED medications currently on the market–Viagra, Levitra, and Cialis–all work by the same means, and they have similar side effects. (Source: ScienceDaily Headlines)
Drug: Lexapro Case caption: Melissa Estevez v. Forest Laboratories Inc., et al.? No. 07-CV-2945 Court: D. N.J. Full story on lexis.com (Source: LexisNexis® Mealey’s™ Antidepressant Drugs Legal News)
Sepracor Inc. has filed plans to seek European marketing approval for its anti-insomnia drug Lunesta, representing a bid to boost the drug’s market reach even as generic competition at home cut into net income. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
MedWorm Message: Register for MedMatcha, MedWorm’s medical advertising network, and receive $5 free advertising.
Sepracor Inc. reports two advancements outside the United States for its sleep drug Lunesta. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Submission to European Medicines Agency (EMEA) Earlier Than Expected MAA Includes Eszopiclone Co-Morbidity Data Comprised of Studies in Patients with Insomnia and Co-Morbid Depression, Generalized Anxiety Disorder, Rheumatoid Arthritis, and in Women in … BiopharmaceuticalsSepracor, LUNIVIA, eszopiclone, LUNESTA, insomnia (Source: HSMN NewsFeed)
Manhattan Research, a healthcare market research services firm, today announced the leading pharmaceutical product website destinations for physicians from its new physician research study, “ePharma Physician(R) v7.0: The Future of Professional eMarketing.” Top 10 Pharma Product Websites Among Physicians in 2007 Ranked by Number of U.S. Primary Care Physician Visitors 1. Januvia 2. Singulair 3. [click link for full article] (Source: IT / Internet / E-mail News From Medical News Today)
Happy Friday, dLifers! Today we have another preview post from the soon-to-be launched Blogabetes, this time from Robert Rummel-Hudson: My Year of Living Dangerously I am going to begin this, my very first blog post here, with a confession. I have fallen off the wagon. Not the booze wagon; even before my type 2 diagnosis in February 2006, my drinky drink days were mostly behind me. (College was fun, from what I remember.) No, the wagon I have fallen off of is the healthy living, weight-losing, diabetic-under-control wagon. When I was diagnosed with type 2 diabetes last year, my a1c was hovering above 10, and I was about 35 pounds overweight. I was also terrified. I was 38 years old, with that big number (let’s call it “thirty-ten”) looking in the near future. My own father died at the…
Collaboration is the first partnership for expansion of the LUNESTA(R) brand eszopiclone franchise outside of U.S. Eisai to complete development of eszopiclone in Japan and will have exclusive marketing rights
to the product for the Japanese market … BiopharmaceuticalsSepracor, Eisai, eszopiclone, LUNESTA (Source: HSMN NewsFeed)
Unfortunately, we cannot answer this question. We found no guidance on the management of patients with asymptomatic bacteraemia wanting to have an LNG-IUS fitted. (Source: NLH Question Answering Service)
Topiramate (Topamax), an effective seizure disorder treatment, received additional FDA approval for prevention of migraine headaches in August 2004 and has gained attention for its off-label uses, including psychiatric and eating disorders, neuropathic pai… (Source: SafetyLit: All (Unduplicated))